On May 2, 2023 NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors to perform in vivo gene editing without triggering the immune system, reported two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy ("ASGCT") 26th Annual Meeting, which will take place in Los Angeles, CA and virtually on May 16-20, 2023 (Press release, NeuBase Therapeutics, MAY 2, 2023, View Source [SID1234630850]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the oral presentations are listed below, and the full abstracts are available on the ASGCT (Free ASGCT Whitepaper) meeting website.

Title: Toxicology, Pharmacokinetics and Biodistribution of a PATrOL-Enabled Investigational Genetic Therapy for Myotonic Dystrophy, Type 1
Presenter: Dr. William Riedl
Presentation Time: 1:45 PM – 2:00 PM PT
Session Date/Time: Thursday, May 18, 2023; 1:30 PM – 3:15 PM PT
Session Title: Gene Therapy Approaches for Muscle and Skeletal Diseases
Room: Room 408 AB
Abstract Number: 131

Title: Nuclease-Free Gene Editing with Peptide Nucleic Acids: A New Class of In Vivo Gene Editors
Presenter: Dr. Dani Stoltzfus
Presentation Time: 8:30 AM – 8:45 AM PT
Session Date/Time: Saturday, May 20, 2023; 8:00 AM – 9:45 AM PT
Session Title: Genome & Epigenome Editing Technologies II
Room: Concourse Hall 152 & 153
Abstract Number: 335